Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Modern skincare brands operate in a highly regulated global environment where ingredient traceability and safety documentation are essential
GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
Side Effects and Safety Profiles Shared Side Effects Both compounds share a similar gastrointestinal (GI) side-effect profile, typical of the GLP-1 class
Fitzpatrick, A
US$ 28.90
US$ 27.05
US$ 25.67
US$ 27.08
US$ 23.60
